TARDBP and frontotemporal dementia: Preferential targeting of astrocytes via A-MAD could lead to significant benefits for the treatment of Transactive response DNA binding protein of 43 kDa (TDP-43)-related proteinopathies, such as ALS and frontotemporal dementia (FTD), where astrocyte activation and inflammation appear as strong effectors in disease progression (109).